Back to top

pharmaceuticals: Archive

Zacks Equity Research

Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug

Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.

RHHBY MRK AMGN AGN

Zacks Equity Research

Can Teva (TEVA) Return to Growth in This Year or Next?

Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

TEVA GILD MRK LLY

Kinjel Shah

Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales

FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.

JNJ AZN RHHBY PFE MRK GSK BMY

Ritujay Ghosh

Coronavirus Vaccine Race Pushes Up Pharma Giants' Production

Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.

SNY PFE MRNA BNTX

Zacks Equity Research

Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

RDY VRTX ABBV

Zacks Equity Research

AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer

FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.

AZN PFE MRK CLVS

Zacks Equity Research

Will Milestone Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor of Milestone Pharmaceuticals

MIST

Zacks Equity Research

These 4 High Earnings Yield Stocks are Hot Investment Picks

Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.

GILD CEMI BMY BTG

Zacks Equity Research

J&J to Stop Sale of Talc-Based Baby Powder in North America

J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

JNJ PFE LLY ABBV

Zacks Equity Research

AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC

The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.

AZN LLY GSK INVA

Zacks Equity Research

Glaxo's Long-Acting HIV Injection Effective Than Daily Pills

Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.

JNJ PFE GILD GSK

Zacks Equity Research

Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA

Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.

BIIB RHHBY NVS BAYRY

Zacks Equity Research

Roche's Tecentriq Gets FDA Approval for Metastatic NSCLC

Roche (RHHBY) gets FDA approval for the label expansion of Tecentriq into metastatic NSCLC as a first-line monotherapy.

AZN RHHBY MRK BMY

Ritujay Ghosh

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

REGN SNY PFE GILD MRNA GSK AMGN CYDY ADPT BNTX

Kevin Cook

Bull of the Day: Vertex Pharma (VRTX)

While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth

VRTX CRSP

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for May 19th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 19th

UNFI SYRS MIST AGFS

Tirthankar Chakraborty

New Strong Buy Stocks For May 19th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

MTSI HCFT FARO AT ABBV

Sheraz Mian

Top Stock Reports for Facebook, JNJ, FIS & Others

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Johnson & Johnson (JNJ) and Fidelity National Information Services, Inc. (FIS).

JNJ FIS FB CMCSA BMY BABA

Zacks Equity Research

Bristol Myers' Opdivo+Yervoy Gets FDA Nod in First-Line NSCLC

Bristol-Myers (BMY) Opdivo in combination with Yervoy gets FDA nod for the first-line treatment of NSCLC patients.

AZN RHHBY MRK BMY

Zacks Equity Research

Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

PFE SRPT PTCT SLDB

Mark Vickery

Moderna (MRNA) COVID-19 Vaccine Looks Promising

This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.

MRNA SPY QQQ DIA

Sheraz Mian

Q1 Scorecard and Research Reports for NVIDIA, Coca-Cola, PetroChina & Others

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Coca-Cola (KO) and PetroChina (PTR).

ZM QCOM PTR NVDA KO CVS

Zacks Equity Research

Merck's (MRK) Keytruda Successful in Several Cancer Studies

Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.

RHHBY MRK BMY SGEN

Kinjel Shah

Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY

FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.

SNY AZN MRK LLY BMY ABBV

Zacks Equity Research

Roche Posts Positive Phase II Results on Immunotherapy Combo

Roche's (RHHBY) mid-stage study on immunotherapy, tiragolumab, combined with PD-L1 checkpoint inhibitor, Tecentriq, meets co-primary endpoints.

AZN RHHBY MRK BMY